Abstract
Purpose
To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.
Materials and methods
We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3–6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).
Results
The median survival time was 19 months (range of 3–36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred.
Conclusion
CT-guided 125I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300
Bruix J, Raoul JL, Sherman M et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821–829
Chen F, Sato K, Fujinaga T, Sonobe M et al (2008) Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg 32:2213–2217
Cheng J, Wang W, Zhang Y et al (2014) Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS ONE 9:e87011
Chua TC, Morris DL (2012) Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol 21:95–101
Hu X, Qiu H, Zhang L et al (2012) Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy. Cancer Biol Ther 13:840–847
Hu Z, Li W, Huang P et al (2017) Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection. Int J Surg 48:23–31
Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T, Nakajima J (2012) Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 41:376–382
Koritzinsky M, Wouters BG, Amellem O, Pettersen EO (2001) Cell cycle progression and radiation survival following prolonged hypoxia and re-oxygenation. Int J Radiat Biol 77:319–328
Lee CY, Bae MK, Park IK et al (2010) Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 101:239–243
Li C, Zhang F, Zhang W et al (2010) Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 136:1633–1640
Loukeri AA, Kampolis CF, Ntokou A et al (2015) Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. Clin Lung Cancer 16:15–23
Ma WJ, Wang HY, Teng LS (2013) Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 11:212
Mo Z, Zhang T, Zhang Y et al (2018) Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol 28:1194–1203
Nag S (2000) Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations. Semin Urol Oncol 18:133–136
Natsuizaka M, Omura T, Akaike T et al (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20:1781–1787
Qu A, Wang H, Li J et al (2014) Biological effects of (125)i seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest 32:209–217
Stewart A, Parashar B, Patel M et al (2016) American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy 15:1–11
Sun T, He J, Zhang S, Sun J, Zeng M, Zeng Z (2016) Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. Oncotarget 7:48586–48599
Taketomi A, Toshima T, Kitagawa D, Motomura T et al (2010) Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 17:2740–2746
Tomimaru Y, Sasaki Y, Yamada T et al (2006) The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg 192:46–51
Uchino K, Tateishi R, Shiina S et al (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117:4475–4483
Wang H, Wang J, Jiang Y et al (2013) The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res 32:106
Wang G, Zhang F, Yang B et al (2016) Feasibility and clinical value of CT-guided (125)I brachytherapy for bilateral lung recurrences from colorectal carcinoma. Radiology 278:897–905
Xiang Z, Li G, Liu Z et al (2015) 125I brachytherapy in locally advanced non-small cell lung cancer after progression of concurrent radiochemotherapy. Medicine (Baltimore) 94:e2249
Yan H, Mo Z, Xiang Z et al (2017) CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer 8:2104–2113
Yang G, Peng S, Zhang Y et al (2014) Cell-based assay system to estimate the effect of 125I seeds on cancer cells: effect of osteopontin. Recent Pat Anticancer Drug Discov 9:258–263
Zhang FJ, Li CX, Jiao DC et al (2008) CT guided 125 iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. Chin Med J (Engl) 121:2410–2414
Zhang L, Chen LH, Wang J et al (2014) CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma. Clin Radiol 69:624–629
Zhou D, Shao L, Spitz DR (2014) Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res 122:1–67
Funding
This study was funded by national natural science foundation of China (Grant Nos. 81371654 to Fujun Zhang and 81571780 to Fei Gao) and Natural Science Foundation of Guangdong Province (Grant No. 2018A0303130050 to Chun Wu).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All individual participants agreed the study and signed informed consent. This work was supported by the institutional review board (the Research Data Deposit Number is RDDA2018000894).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xiang, Z., Bai, M., Li, G. et al. Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. J Cancer Res Clin Oncol 145, 1907–1916 (2019). https://doi.org/10.1007/s00432-019-02943-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02943-x